Abstract
Cystoid macular edema (CME) is a severe complication and a major cause of visual loss in patients with intraocular infection. In this type of CME, therapeutic strategies remain controversial. We aimed to investigate the efficacy and tolerability of interferon (IFN)-α2a in cystoid macular edema caused by intraocular infection. In this retrospective, noncomparative, interventional case series, 5 patients (6 eyes) who were diagnosed with intraocular infection with chronic CME were included. Interferon-α2a (3 million units 3 times a week) was administered subcutaneously. Clinical observations were recorded before and after treatment. The average duration of CME before treatment with IFN-α was 26 months. According to the preset criteria, IFN-α2a therapy was shown to be effective in 2 patients (3 eyes), effective dose-dependent in 2 patients, and partly effective in 1 patient, and was well-tolerated in 4 patients. The most common side effect was flu-like symptoms. Interferon α-2a may be an effective alternative treatment for CME due to intraocular infection that is resistant to other treatment. Studies with larger sample sizes are required to confirm this conclusion.
References
Jun 4, 1994·Lancet·E J FeronM S Suttorp-Schulten
Apr 1, 1996·The British Journal of Ophthalmology·A RothovaA Kijlstra
Apr 28, 1999·Lancet·C P LohmannJ Preuner
Feb 13, 2003·Ophthalmology·Joel A SchulmanJohn King
Mar 19, 2003·The British Journal of Ophthalmology·I KötterN Stübiger
Apr 6, 2004·Leukemia & Lymphoma·A AlabdulaalyJ H Lipton
Oct 19, 2004·American Journal of Ophthalmology·Nikos N MarkomichelakisPetros P Sfikakis
Apr 5, 2005·Ocular Immunology and Inflammation·Güngör SobaciAtilla Bayer
Oct 1, 2005·American Journal of Ophthalmology·Douglas A JabsUNKNOWN Standardization of Uveitis Nomenclature (SUN) Working Group
Oct 18, 2005·American Journal of Ophthalmology·Emmanuelle BrasnuBahram Bodaghi
May 26, 2006·The British Journal of Ophthalmology·P TranosD G Charteris
Sep 12, 2006·Retina·Christoph M E DeuterManfred Zierhut
Oct 20, 2006·The British Journal of Ophthalmology·Bahram BodaghiJean-Charles Piette
Jan 12, 2007·The British Journal of Ophthalmology·Gerald A Fishman, Marsha A Apushkin
Jul 3, 2007·American Journal of Ophthalmology·Jarka PlskovaJohn V Forrester
Jan 11, 2008·Retina·Friederike MackensenArnd Heiligenhaus
Mar 27, 2009·The British Journal of Ophthalmology·C M E DeuterM Zierhut
Feb 26, 2010·Journal français d'ophtalmologie·V PaireM Weber
Nov 3, 2010·Ocular Immunology and Inflammation·Annette Ossewaarde-van Norel, Aniki Rothova
Mar 23, 2011·Nature Reviews. Gastroenterology & Hepatology·Hellan Kwon, Anna S Lok
Jun 24, 2011·The New England Journal of Medicine·Hugo R Rosen
Apr 24, 2012·Acta Ophthalmologica·Dicle HazirolanUwe Pleyer
Jan 1, 2011·European Journal of Ophthalmology·Marc D de Smet, Karina Julian
Jun 22, 2013·American Journal of Ophthalmology·Friederike MackensenMatthias D Becker
Citations
Apr 6, 2019·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Natalia LewczukJoanna Bogusławska
Jun 5, 2019·Ocular Immunology and Inflammation·Hilal Eser-Ozturk, Yuksel Sullu
Feb 23, 2018·Ocular Immunology and Inflammation·Alessandro InvernizziLuca Cimino
Dec 11, 2019·Ocular Immunology and Inflammation·Chloé CouretMichel Weber
Feb 15, 2020·Ocular Immunology and Inflammation·Aleksandra RadosavljevicManfred Zierhut
Mar 7, 2019·Retina·Mehrdad AfaridMohammad Mostafa Safarpour
Apr 18, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Merih OrayIlknur Tugal-Tutkun
Jul 31, 2021·World Journal of Diabetes·Bing-Yan LiYe-Di Zhou
Aug 5, 2021·Ocular Immunology and Inflammation·Nihan Aksu-CeylanIlknur Tugal-Tutkun